Zoetis to Host Innovation Webcast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2025
0mins
Should l Buy ZTS?
Source: Newsfilter
Zoetis Inc. will conduct an Innovation Webcast on December 2, 2025, where key executives will discuss the company's pipeline and strategic approach to animal health.
The webcast will feature insights from Dr. Kevin Esch, who will succeed Dr. Rob Polzer as President of Research and Development effective January 1, 2026. This leadership transition is expected to bring fresh perspectives to Zoetis' research initiatives.
As a leading animal health company, Zoetis generated $9.3 billion in revenue in 2024 and employs approximately 13,800 people. The webcast aims to highlight the company's commitment to advancing care for animals.
Investors can access the live webcast via the Zoetis website, with pre-registration available. A replay will also be provided after the event.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZTS is 154.20 USD with a low forecast of 130.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 126.730
Low
130.00
Averages
154.20
High
200.00
Current: 126.730
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Earnings Reports and Economic Outlook This Week
- DuPont Earnings Expectations: DuPont is expected to report earnings of $0.43 per share and revenue of $1.69 billion for Q4 2025, with analysts noting ongoing pressure in short-cycle businesses, while slight improvements in the automotive sector may influence investor sentiment.
- Cisco's AI Focus: Cisco anticipates earnings of $1.02 per share and revenue of $15.1 billion for Q2 FY2026, with CEO highlighting a major multi-year campus networking refresh, making AI infrastructure demand a critical growth driver.
- Importance of Employment Report: The January employment report is expected to show an addition of 80,000 nonfarm payrolls and an unchanged unemployment rate of 4.4%, directly impacting private consumption and U.S. GDP, making it crucial for investors to monitor.
- Consumer Price Index Insights: The January CPI is projected to increase by 2.5% year-over-year, with core CPI rising by 2.6%, providing essential inflation details despite not being the Fed's preferred measure, particularly regarding persistent shelter cost inflation.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Gold and Silver Aren't the Sole Hot Commodities: Explore Agricultural Stocks.
Focus on Soft Commodities: The article emphasizes the importance of paying attention to soft commodities, which are often overshadowed by the rally in hard commodities like gold and silver.
Market Dynamics: It suggests that the current market dynamics warrant a closer look at soft commodities, as they may present significant investment opportunities.
See More
Zoetis and Regeneron Gain Approvals, Positive Market Outlook Ahead
- Zoetis New Drug Approval: Zoetis has received approvals for Lenivia and Portela, its next-gen osteoarthritis pain treatments for dogs and cats, which will help the company maintain a strong market share and improve its financial performance in 2023.
- Market Competition Pressure: Despite competition from products like Apoquel, Zoetis still has significant market potential in the pet health sector, which is expected to drive the company's recovery in 2026.
- Regeneron Drug Expansion: Regeneron has gained approval for a higher-dose version of Eylea and expanded its indications, allowing it to serve a larger patient pool with a more convenient dosing schedule, enhancing its market competitiveness.
- Strong Growth Drivers: Regeneron's Dupixent remains a key growth driver, and the company's pipeline candidates in weight management will further bolster its market performance, with expectations of delivering market-beating returns.
See More
Zoetis (ZTS) Stock Drops to Historic Low, Future Turnaround Expected
- Stock Decline: Zoetis has seen its stock rise 480% since going public, but it has recently slid nearly 40%, reflecting underwhelming quarterly performances against a stretched valuation, with the current P/E ratio at a historic low of 21.
- R&D Potential: The company anticipates at least one major market approval annually over the next several years, with 12 new therapies having blockbuster potential, indicating a robust R&D pipeline.
- Market Opportunity: Zoetis's core R&D markets for chronic kidney failure, oncology, and cardiology are expected to represent a $5 billion market opportunity, compared to its annual sales of $9.3 billion, underscoring its leadership in the animal healthcare sector.
- Sustained Growth: Despite the stock decline, Zoetis has achieved an 8% annual sales growth since 2013, and it is expected to maintain this momentum, especially as the global animal healthcare market is projected to grow by 5% to 6% annually.
See More
Key Earnings Reports and Economic Outlook This Week
- DuPont Earnings Expectations: DuPont is expected to report earnings of $0.43 per share and revenue of $1.69 billion for Q4 2025, with analysts noting ongoing pressure in short-cycle businesses, while slight improvements in the automotive sector may influence investor sentiment.
- Cisco's AI Focus: Cisco anticipates earnings of $1.02 per share and revenue of $15.1 billion for Q2 FY2026, with CEO highlighting a major multi-year campus networking refresh, making AI infrastructure demand a critical growth driver.
- Importance of Employment Report: The January employment report is expected to show an addition of 80,000 nonfarm payrolls and an unchanged unemployment rate of 4.4%, directly impacting private consumption and U.S. GDP, making it crucial for investors to monitor.
- Consumer Price Index Insights: The January CPI is projected to increase by 2.5% year-over-year, with core CPI rising by 2.6%, providing essential inflation details despite not being the Fed's preferred measure, particularly regarding persistent shelter cost inflation.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
Gold and Silver Aren't the Sole Hot Commodities: Explore Agricultural Stocks.
Focus on Soft Commodities: The article emphasizes the importance of paying attention to soft commodities, which are often overshadowed by the rally in hard commodities like gold and silver.
Market Dynamics: It suggests that the current market dynamics warrant a closer look at soft commodities, as they may present significant investment opportunities.
See More
Zoetis and Regeneron Gain Approvals, Positive Market Outlook Ahead
- Zoetis New Drug Approval: Zoetis has received approvals for Lenivia and Portela, its next-gen osteoarthritis pain treatments for dogs and cats, which will help the company maintain a strong market share and improve its financial performance in 2023.
- Market Competition Pressure: Despite competition from products like Apoquel, Zoetis still has significant market potential in the pet health sector, which is expected to drive the company's recovery in 2026.
- Regeneron Drug Expansion: Regeneron has gained approval for a higher-dose version of Eylea and expanded its indications, allowing it to serve a larger patient pool with a more convenient dosing schedule, enhancing its market competitiveness.
- Strong Growth Drivers: Regeneron's Dupixent remains a key growth driver, and the company's pipeline candidates in weight management will further bolster its market performance, with expectations of delivering market-beating returns.
See More
Zoetis (ZTS) Stock Drops to Historic Low, Future Turnaround Expected
- Stock Decline: Zoetis has seen its stock rise 480% since going public, but it has recently slid nearly 40%, reflecting underwhelming quarterly performances against a stretched valuation, with the current P/E ratio at a historic low of 21.
- R&D Potential: The company anticipates at least one major market approval annually over the next several years, with 12 new therapies having blockbuster potential, indicating a robust R&D pipeline.
- Market Opportunity: Zoetis's core R&D markets for chronic kidney failure, oncology, and cardiology are expected to represent a $5 billion market opportunity, compared to its annual sales of $9.3 billion, underscoring its leadership in the animal healthcare sector.
- Sustained Growth: Despite the stock decline, Zoetis has achieved an 8% annual sales growth since 2013, and it is expected to maintain this momentum, especially as the global animal healthcare market is projected to grow by 5% to 6% annually.
See More
